| P2093 | author name string | Dave S B Hoon | |
| | Edward S Greenberg | |
| | Kelly K Chong | |
| | Kelly T Huynh | |
| P2860 | cites work | MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer | Q21195215 |
| | Translating the Histone Code | Q22065840 |
| | DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci | Q22254582 |
| | The Polycomb group protein EZH2 directly controls DNA methylation | Q24299020 |
| | An operational definition of epigenetics | Q24568002 |
| | miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA | Q24644154 |
| | MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer | Q24645663 |
| | CpG island methylator phenotype in colorectal cancer | Q24672170 |
| | EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells | Q24672969 |
| | Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein | Q24682617 |
| | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response | Q27694612 |
| | MicroRNA gene expression deregulation in human breast cancer | Q27860690 |
| | Chromatin modifications and their function | Q27861067 |
| | Role of histone H3 lysine 27 methylation in Polycomb-group silencing | Q28131795 |
| | Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells | Q28256740 |
| | Cadherin switch in tumor progression | Q28262569 |
| | The epigenomics of cancer | Q28289975 |
| | Epigenetics in cancer | Q29547853 |
| | miR-21-mediated tumor growth | Q29616149 |
| | Epigenetics in cancer | Q29617139 |
| | Epigenetic modifications and human disease | Q29619753 |
| | American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer | Q30494798 |
| | CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer | Q33235269 |
| | Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer | Q33362180 |
| | An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. | Q33533878 |
| | DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status | Q33708624 |
| | Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status | Q33769803 |
| | Estrogen receptor-alpha methylation predicts melanoma progression | Q33797076 |
| | Involvement of members of the cadherin superfamily in cancer | Q33899441 |
| | Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns | Q34048118 |
| | Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience | Q34187884 |
| | Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma | Q34254446 |
| | Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. | Q34506613 |
| | Aberrant DNA methylation in malignant melanoma | Q34516587 |
| | MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis | Q34835189 |
| | MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways | Q34868281 |
| | A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer | Q35034708 |
| | Delineating an epigenetic continuum for initiation, transformation and progression to breast cancer | Q35110475 |
| | Breast cancer methylomes establish an epigenomic foundation for metastasis | Q35136051 |
| | Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression | Q35636561 |
| | microPrimer: the biogenesis and function of microRNA. | Q36285669 |
| | Array-based multiplex analysis of DNA methylation in breast cancer tissues | Q36329331 |
| | Correlation between CpG methylation profiles and hormone receptor status in breast cancers | Q36393321 |
| | DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines | Q36465214 |
| | MicroRNA-cancer connection: the beginning of a new tale | Q36555283 |
| | Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. | Q36787353 |
| | Epigenomics and breast cancer | Q37078784 |
| | CpG island methylator phenotype predicts progression of malignant melanoma | Q37245444 |
| | Epigenetic cross-talk between DNA methylation and histone modifications in human cancers | Q37314994 |
| | Targeting DNA methylation | Q37320354 |
| | Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment | Q37324446 |
| | ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers | Q37407136 |
| | Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells | Q37515409 |
| | The epigenetics of breast cancer | Q37772356 |
| | Molecularly targeted endocrine therapies for breast cancer. | Q37815616 |
| | Cancer epigenetics reaches mainstream oncology | Q37851012 |
| | Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. | Q38422359 |
| | Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. | Q39690990 |
| | ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor | Q40014619 |
| | The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. | Q40168734 |
| | Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation | Q40195308 |
| | Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes | Q40266897 |
| | Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer | Q40490715 |
| | Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. | Q42452150 |
| | Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. | Q44653608 |
| | A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. | Q44657529 |
| | Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus | Q45419139 |
| | Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. | Q45948475 |
| | Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. | Q51535040 |
| | Promoter CpG island hypermethylation during breast cancer progression. | Q53449089 |
| | Estrogen receptors: role in breast cancer. | Q53595317 |
| | CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. | Q54456631 |
| | Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma | Q57161281 |
| P433 | issue | 4 | |
| P921 | main subject | epigenetics | Q26939 |
| P304 | page(s) | 371-382 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare | Q15756305 |
| P1476 | title | Epigenetics of estrogen receptor-negative primary breast cancer | |
| P478 | volume | 12 | |